Adamas Pharmaceuticals (ADMS) Reiterated Outperform After Gocovri Accepted for Review - William Blair
Tweet Send to a Friend
William Blair analyst Tim Lugo reiterated an Outperform rating on Adamas Pharmaceuticals (NASDAQ: ADMS) after the company announced the FDA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
